Australian medical cannabis pioneer Little Green Pharma (ASX:LGP) reports the arrival of over 6,500 units of 3 new LGP-branded high-THC medicinal cannabis flower products into the Australian market from its Danish facility.
The entry of these products represents the commercialisation of the company’s Danish facility and comes following an 18-month journey from initial strain development and production at the facility since the company acquired the facility in July last year.
It is also reported these new products ‘significantly’ expand the LGP flower portfolio and enhance its competitiveness in the rapidly growing Australian flower market.
The company also notes that ownership of the supply chain provides it with enhanced production availability, reliability, improved cost and quality control.
In addition to these 3 new products, it is also anticipating the arrival of a further 4,000 units of 4th new flower product concept offering from its Danish facilities in December this year.
LGP was founded in 2016 with the aim of improving the quality of life for children debilitated by seizures and in 2018 it successfully pioneered the Australian medical cannabis market with the launch of the nation’s first locally grown cannabis medicine. The company’s medication was half the price of the imported options at the time in order to support Australian patients.
LGP currently own 2 global production sites for the manufacturing of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500m-square cultivation and 4,000m-square GMP manufacturing facility capable of producing about 30 tonnes of medicinal cannabis biomass per annum located in Denmark, as well as an indoor facility located in Western Australia (WA).
With the new products now delivered, LGP announces that 10 additional strains in various stages of development are also intended for supply into the Australian and other markets in the coming quarters.
